상세 보기
Ciltacabtagene Autoleucel (Cilta-cel) vs Standard of Care (SOC) in Patients With Lenalidomide (Len)-Refractory Multiple Myeloma (MM) After 1-3 Lines of Therapy: Minimal Residual Disease Negativity (MRD-neg) in the Phase 3 CARTITUDE-4 Trial
- Einsele, H.;
- Oriol, A.;
- Popat, R.;
- Cavo, M.;
- Karlin, L.;
- ... Kim, S. J.;
- 외 21명
Citations
WEB OF SCIENCE
0Citations
SCOPUS
0- 제목
- Ciltacabtagene Autoleucel (Cilta-cel) vs Standard of Care (SOC) in Patients With Lenalidomide (Len)-Refractory Multiple Myeloma (MM) After 1-3 Lines of Therapy: Minimal Residual Disease Negativity (MRD-neg) in the Phase 3 CARTITUDE-4 Trial
- 저자
- Einsele, H.; Oriol, A.; Popat, R.; Cavo, M.; Karlin, L.; Avivi, L.; Roelofzen, W.; Kim, S. J.; Lipe, B.; Bar, N.; Horvath, N.; Spencer, A.; Min, C. -K.; Chen, D.; Li, Q.; Li, K.; Slaughter, A.; Lonardi, C.; Benachour, N.; Ghosh, A.; Vogel, M.; Lendvai, N.; Lengil, T.; Patel, N.; Filho, O. Costa; Florendo, E.; Lin, Y.
- 발행일
- 2025-10-20
- 유형
- Meeting Abstract
- 권
- 48
- 호
- SUPPL 2